Abstract 311P
Background
Endometrial cancer (EC) is the most common gynecological malignancy worldwide. Therefore, early diagnosis of EC is critical. Routine endometrial cytology has low sensitivity and specificity. If there are few endometrial cells and there are no obvious signs of atypia, knowledge of additional diagnostic criteria will help identify pathological processes in the endometrium. The aim of the study was to evaluate the diagnostic significance of serum cytokines in patients with EC and uterine myoma (UM).
Methods
The blood serum of primary patients with stage I (initial) EC (n=42) according to FIGO was studied. The mean age of patients was 37-77 years, and patients with UM (n=20) (41-59 years). The control group included 30 practically healthy female donors (23-65 years). The level of IL1RA, IL17A (Cytokin, Russia), IL1β, 2, 4, 6, 8, 10, 18, TNFα, IFNγ and MCP- 1 (VBV, Russia) in pg/ml. The results were expressed as IQRQ1-Q3. The study was carried out in accordance with the requirements of the Ethics Commission of the Institute of ME&PhC of UlSU. Statistical analysis was performed using Jamovi 1.6.5.0.
Results
A significant increase in the level of IL1RA in the blood serum of patients at stage I EC at UM (p=0.002) and relative to control (p=0.001). The concentration of circulating IL6 was significantly increased at initial EC compared with UM (p=0.044). MCP-1 in the serum of patients with UM is reduced compared with the control group (p=0.013). At stage I EC, the level of MCP-1 in serum is significantly higher compared with control (p=0.012) and UM (p=0.005). The levels of other cytokines did not show significant differences with the control group in the presented model. In a univariate logistic regression analysis for the differential diagnosis between UM and EC, statistical significance was jointly demonstrated by IL1RA and serum IL6/MCP-1 The risk of EC increases with concomitantly elevated serum levels of IL1RA and IL6 (R2=0.82, χ2=30.5, p=0.001) with a probability of 96.2% (Spec.=0.80, Sens.=0.96), as well as with simultaneously elevated levels of IL1RA and MCP-1 (R2=0.75, χ2=26.4, р=0.001) with 88.5% probability (Spec.=0.80, Sens.=0.88).
Conclusions
Evaluation of the serum level of IL1RA, IL6, MCP-1 can be used in the differential diagnosis of EC and UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract